DR. ROBERT IRVING LEHRER, M.D.
Osteopathic Medicine at Washington Ave, Santa Monica, CA

6492328, Dec 10, 2002

Apr 19, 2001

09/840009

Robert I. Lehrer - Santa Monica CA
Alan J. Waring - Irvine CA
Brian F. Tack - Iowa City IA

The University of Iowa Research Foundation - Iowa City IA
The Regents of the University of California - Oakland CA

A61K 3800

514 2, 530300, 530326

Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.

6159936, Dec 12, 2000

Aug 3, 1998

9/128345

Robert I. Lehrer - Santa Monica CA
Sylvia S. L. Harwig - Woodland Hills CA
Vladimir N. Kokryakov - St. Petersburg, RU

The Regents of the University of California - Oakland CA

A61K 3804, C07K 700, C12N 1512, C12P 2102, C12P 2104

514 13

Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin. These compounds, in one embodiment, are of the formula: A. sub. 1 --A. sub. 2 --A. sub. 3 --A. sub. 4 --A. sub. 5 --A. sub. 6 --A. sub. 7 --A. sub. 8 --A. sub. 9 --A. sub. 10 --A. sub. 11 --A. sub. 12 --A. sub. 13 --A. sub. 14 --A. sub. 15 --A. sub. 16 --(A. sub. 17 --A. sub. 18) (1) and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, which is either in the optionally --SH stablizied linear or in a cystine-bridged form wherein each of A. sub. 1 and A. sub. 9 is independently a basic amino acid; each of A. sub. 2 and A. sub. 3 is independently a small amino acid; each of A. sub. 5, A. sub. 7, A. sub. 12, A. sub. 14 and A. sub.

5889152, Mar 30, 1999

Jun 7, 1995

8/477131

Sylvia S.L. Harwig - Woodland Hills CA
Robert I. Lehrer - Santa Monica CA

Regents of the University of California - Oakland CA

C07K 1447, C07K 900, C07K 706, C07K 510

530350

Peptide-based compounds containing multiple proline residues are useful as preservatives and in preventing, treating, or ameliorating microbial infection, especially Gram-negative bacterial infection in animals and plants, in treating conditions characterized by the presence of LPS. These compounds are of the formula ##STR1## including the N-terminal acylated and/or C-terminal amidated or esterified forms thereof wherein each of A. sub. 1, A. sub. 5, A. sub. 10, A. sub. 14 and A. sub. 20 is independently Ala, Gly or Ser; each of A. sub. 2, A. sub. 4, A. sub. 7, A. sub. 9, A. sub. 11, A. sub. 12, A. sub. 13, A. sub. 16, A. sub. 17, A. sub. 19 and A. sub. 22 is independently a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met; each of A. sub. 3 and A. sub. 8 is independently a neutral polar amino acid selected from Asn and Gln or is a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met; each of A. sub. 6, A. sub. 18 and A. sub. 21 is independently a basic amino acid selected from Arg, Lys, and Har; and wherein A. sub.

7071293, Jul 4, 2006

Aug 18, 2000

09/642744

Brian F. Tack - Iowa City IA, US
Michael Welsh - Riverside IA, US
Sue M. Travis - Iowa City IA, US
Robert Lehrer - Santa Monica CA, US

The University of Iowa Research Foundation - Iowa City IA
The Regents of the University of California - Oakland CA

A61K 38/00, A61K 38/04, C07K 14/00, C07K 16/00, C07K 17/00, C07K 5/00, C07K 7/00

530300, 530324, 530325, 530326, 530327, 514 12

The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.

5635594, Jun 3, 1997

Mar 11, 1994

8/212236

Robert I. Lehrer - Santa Monica CA
Sylvia S. L. Harwig - Woodland Hills CA

University of California, Los Angeles - Los Angeles CA

C07K 14435, C07K 14465, A61K 3817

530317

Peptide-based compounds containing six invariant cysteine residues are useful as preservatives and in preventing, treating, or ameliorating microbial infection in animals and plants. These compounds are of the formulas: ##STR1## wherein each B. sub. i is a basic amino acid and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, either in optionally --SH stabilized linear or in cystine-bridged form.

5708145, Jan 13, 1998

May 17, 1994

8/243879

Robert I. Lehrer - Santa Monica CA
Sylvia S.L. Harwig - Woodland Hills CA

University of California - Los Angeles CA

C07K 1644

5303871

Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin. These compounds, in one embodiment, are of the formula: A. sub. 1 -A. sub. 2 -A. sub. 3 -A. sub. 4 -A. sub. 5 -C-A. sub. 7 -C-A. sub. 9 -A. sub. 10 -A. sub. 11 -A. sub. 12 -C-A. sub. 14 -C-A. sub. 16 -(A. sub. 17 -A. sub. 18)(1) and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, either in optionally --SH stabilized linear or in cystine-bridged form wherein A. sub. 1 and A. sub. 9 are basic amino acids; A. sub. 2, A. sub. 3 and A. sub. 10 are small amino acids; A. sub. 5, A. sub. 7, A. sub. 12, A. sub. 14 and A. sub.

7314858, Jan 1, 2008

Nov 5, 2004

10/982145

Robert I. Lehrer - Santa Monica CA, US
Alan J. Waring - Irvine CA, US
Alexander M. Cole - Orlando FL, US
Teresa B. Hong - El Monte CA, US

The Regents of the University of California - Oakland CA

A61K 38/00, C07K 7/00, C07K 7/04, C07K 7/64

514 2, 514 9, 514 15, 530300, 530317, 530326, 530328

Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.

2004015, Aug 5, 2004

Jul 24, 2003

10/627829

Robert Lehrer - Santa Monica CA, US
Sylvia Harwig - Woodland Hills CA, US
Vladimir Kokryakov - St. Petersburg, RU

The Regents of the University of California

A61K038/10, C07K007/08

514/013000, 530/326000

Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin. These compounds, in one embodiment, are of the formula: and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, which is either in the optionally —SH stablizied linear or in a cystine-bridged form wherein each of Aand Ais independently a basic amino acid; each of Aand Ais independently a small amino acid; each of A, A, A, Aand Ais independently a hydrophobic amino acid; Ais a basic or a small amino acid; Ais a basic or a small amino acid or is proline; Ais a basic or hydrophobic amino acid; Ais not present or, if present, is a small amino acid; Ais not present or, if present, is a basic amino acid; or a modified form of formula (1) and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof wherein each of 1-4 cysteines is independently replaced by a hydrophobic amino acid or a small amino acid.

6040293, Mar 21, 2000

Feb 28, 1997

8/810324

Robert I. Lehrer - Santa Monica CA
Chengquan Zhao - Los Angeles CA
In-Hee Lee - Seoul, KR

The Regents of the University of California - Los Angeles CA

C07K 1400, A61K 3702

514 13

Novel microbial peptides called clavanins are of the formula [X'. sub. 1 X. sub. 2 B'. sub. 3 X. sub. 4 X. sub. 5 ]U. sub. 6 B. sub. 7 X. sub. 8 X. sub. 9 B. sub. 10 B. sub. 11 X. sub. 12 U. sub. 13 Z. sub. 14 X. sub. 15 X. sub. 16 B*. sub. 17 U. sub. 18 X. sub. 19 U. sub. 20 B. sub. 21 X. sub. 22 X. sub. 23 ( 1)(SEQ ID NO:1 ) including the salts, esters, amides and acylated forms thereof wherein X is a hydrophobic amino acid residue or modified form thereof; X' is a small or a hydrophobic amino acid residue or a modified form thereof; B is a basic amino acid residue or modified form thereof; B' is basic or a polar/large amino acid residue or modified form thereof; and B* is a basic or a hydrophobic amino acid residue or a modified form thereof; U is a small amino acid residue or modified form thereof; Z is a polar/large amino acid residue or modified form thereof, and wherein 1-5 amino acids is deleted from the N-terminus.